Derivatization enhanced separation and sensitivity of long chain-free fatty acids: Application to asthma using targeted and non-targeted liquid chromatography-mass spectrometry approach

Bian, Xiqing; Sun, Baoqing; Zheng, Peiyan; Li, Na; Wu, Jian‐Lin

doi:10.1016/j.aca.2017.08.009

Cited by 54 publications

(44 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The derivatization was performed using our previously developed cholamine derivatization UHPLC-Q-TOF/MS approach 16. The residue of 50 μL aliquot of standards or real samples was sequentially mixed with 5 µL of 20 mM HOBt in DMSO, 10 µL of 100 mM cholamine in DMSO containing 200 mM TEA, 5 µL of 20 mM HATU in DMSO, and then incubated at room temperature for 1 min.…”

Section: Methodsmentioning

confidence: 99%

“…hinder their use. Fortunately, our previously reported approaches (2-aminoethyl)trimethylammonium chloride hydrochloride (cholamine) and 5-(diisopropylamino)amylamine derivatization coupled with ultrahigh performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UHPLC-Q-TOF/MS),16,17 as well as solid phase extraction-nano-UHPLC-Q-TOF/MS18 were developed to sensitively and effectively detect eicosanoids. In this study, cholamine derivatization-UHPLC-Q-TOF/MS was applied to investigate eicosanoids in serum samples of COPD, ACO, and control groups.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

<p>Eicosanoids metabolized through LOX distinguish asthma–COPD overlap from COPD by metabolomics study</p>

Cai¹,

Bian²,

Xue³

et al. 2019

COPD

Self Cite

View full text Add to dashboard Cite

Background and objective The prevalence of asthma is greater than 20% in patients previously diagnosed with COPD. Patients with asthma–COPD overlap (ACO) are at risk of rapid progression of disease and severe exacerbations. However, in some patients with ACO, a clear distinction from COPD is very difficult by using physiological testing techniques. This study aimed to apply a novel metabolomic approach to identify the metabolites in sera in order to distinguish ACO from COPD. Methods In the study, blood samples were collected from patients with COPD, ACO, and healthy controls. Cholamine derivatization-ultrahigh performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UHPLC-Q-TOF/MS) was used to investigate serum metabolites of eicosanoids. Results A clear intergroup separation existed between the patients with ACO and those with COPD, while ACO tends to have higher serum metabolic levels of eicosanoids. A robust Orthogonal Projections to Latent Structures-Discriminant Analysis (OPLS-DA) model was found for discriminating between ACO and COPD (R2Y =0.81, Q2=0.79). In addition, there is a significant correlation between some metabolites and clinical indicators, such as hydroxyeicosatetraenoic acids (HETEs), hydroperoxyeicosatetraenoic acids (HPETEs) and FEV1/FVC. The higher values of area under the receiver operating characteristic curves (ROC) of HETEs, which were metabolized from HPETEs through lipoxygenase (LOX), indicated that they should be the potential biomarkers to distinguish ACO from COPD. Conclusion Eicosanoids can clearly discriminate different biochemical metabolic proﬁles between ACO and COPD. The results possibly provide a new perspective to identify potential biomarkers of ACO and may be helpful for personalized treatment.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

<p>Eicosanoids metabolized through LOX distinguish asthma–COPD overlap from COPD by metabolomics study</p>

Cai¹,

Bian²,

Xue³

et al. 2019

COPD

Self Cite

View full text Add to dashboard Cite

show abstract

“…The targeted metabolomic approach was used, which was reported in our previous research [27], and a total of 57 metabolites were identified and relatively quantified in serum of AR patients with SM-SCIT or DM-SCIT. Samples within V0 groups were separated from V2 groups using orthogonal partial least squares discrimination analysis (OPLS-DA) (DM-SCIT: R2 = 0.659, Q2 = 0.026; SM-SCIT: R2 = 0.427, Q2 = −0.0352) models (Supplementary Figure S2).…”

Section: Metabolomics Analysis Of Potential Systemic Biomarkers In Ar Patients With Sm-scit or Dm-scitmentioning

confidence: 99%

Metabolomics Reveals Process of Allergic Rhinitis Patients with Single- and Double-Species Mite Subcutaneous Immunotherapy

et al. 2021

Self Cite

View full text Add to dashboard Cite

Allergen immunotherapy (AIT) is the only treatment that can change the course of allergic diseases. However, there has not been any research on metabolic reactions in relation to AIT with single or mixed allergens. In this study, patients with allergic rhinitis caused by Dermatophagoides pteronyssinus (Der p) and Dermatophagoides farinae (Der f) were treated with single-mite (Der p) and double-mite (Der p:Der f = 1:1) subcutaneous immunotherapy (SCIT), respectively. To compare the efficacy and the dynamic changes of inflammation-related single- and double-species mite subcutaneous immunotherapy (SM-SCIT and DM-SCIT), we performed visual analogue scale (VAS) score, rhinoconjunctivitis quality of life questionnaire (RQLQ) score and serum metabolomics in allergic rhinitis patients during SCIT. VAS and RQLQ score showed no significant difference in efficacy between the two treatments. A total of 57 metabolites were identified, among which downstream metabolites (5(S)-HETE, 8(S)-HETE, 11(S)-HETE, 15(S)-HETE and 11-hydro TXB2) in the ω-6-related arachidonic acid and linoleic acid pathway showed significant differences after approximately one year of treatment in SM-SCIT or DM-SCIT, and the changes of the above serum metabolic components were correlated with the magnitude of RQLQ improvement, respectively. Notably, 11(S)-HETE decreased more with SM-SCIT, and thus it could be used as a potential biomarker to distinguish the two treatment schemes. Both SM-SCIT and DM-SCIT have therapeutic effects on patients with allergic rhinitis, but there is no significant difference in efficacy between them. The reduction of inflammation-related metabolites proved the therapeutic effect, and potential biomarkers (arachidonic acid and its downstream metabolites) may distinguish the options of SCIT.

show abstract

“…Lipid metabolism and oxidative stress. Lipid metabolism is enriched in asthmatics since lipids drive inflammatory responses, promote release of histamine and are essential to cellular energy metabolism (8,9,(11)(12)(13)(14)(15)22,24). The presence of high levels of LDL, VLDL and its hydrolysis products have been found to activate the release of histamine, which promotes constriction of airways smooth muscle (8,12,26).…”

Section: Metabolomics Findingsmentioning

confidence: 99%

Metabolic interactions in asthma

Farraia

Rufo

Paciência

et al. 2019

Eur Ann Allergy Clin Immunol

View full text Add to dashboard Cite

Metabolomics can be used to explore altered metabolic pathways in asthma, giving insights into its pathophysiology. We aimed to review how metabolomics has been used to understand asthma by describing metabolic pathways under research and discussing clinical implications. The search was performed in PubMed, and studies published since 2000 using a metabolomics approach, were included. A total of 32 studies were analysed. Pathways related with cellular energy homeostasis, lipid metabolism and oxidative stress, immune and inflammatory processes and others were altered. Initial studies focused on biomarker discovery. But metabolomics can be used to evaluate drug effects on specific pathways, to highlight pathways that can further develop in new targeted treatments, and to identify differences according to asthma severity and phenotypes.Abbreviations BALF, bronchoalveolar lavage fluid; CS, corticosteroid; EBC, exhaled breath condensate; GCxGC-TOF/MS, two-dimensional gas chromatography with time-of-flight mass spectrom-

show abstract

Derivatization enhanced separation and sensitivity of long chain-free fatty acids: Application to asthma using targeted and non-targeted liquid chromatography-mass spectrometry approach

Cited by 54 publications

References 30 publications

<p>Eicosanoids metabolized through LOX distinguish asthma–COPD overlap from COPD by metabolomics study</p>

<p>Eicosanoids metabolized through LOX distinguish asthma–COPD overlap from COPD by metabolomics study</p>

Metabolomics Reveals Process of Allergic Rhinitis Patients with Single- and Double-Species Mite Subcutaneous Immunotherapy

Metabolic interactions in asthma

Contact Info

Product

Resources

About